Human midbrain dopaminergic neuronal differentiation markers predict cell therapy outcomes in a Parkinson’s disease model

Human pluripotent stem cell–based (hPSC-based) replacement therapy holds great promise for the treatment of Parkinson’s disease (PD). However, the heterogeneity of hPSC-derived donor cells and the low yield of midbrain dopaminergic (mDA) neurons after transplantation hinder its broad clinical applic...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Peibo, He, Hui, Gao, Qinqin, Zhou, Yingying, Wu, Ziyan, Zhang, Xiao, Sun, Linyu, Hu, Gang, Guan, Qian, You, Zhiwen, Zhang, Xinyue, Zheng, Wenping, Xiong, Man, Chen, Yuejun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9282930/
https://www.ncbi.nlm.nih.gov/pubmed/35700056
http://dx.doi.org/10.1172/JCI156768

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9282930/
https://www.ncbi.nlm.nih.gov/pubmed/35700056
http://dx.doi.org/10.1172/JCI156768

Ejemplares similares